852 results on '"Geng, Meiyu"'
Search Results
2. Integrated omics profiling reveals systemic dysregulation and potential biomarkers in the blood of patients with neuromyelitis optica spectrum disorders
3. GV-971 prevents severe acute pancreatitis by remodeling the microbiota-metabolic-immune axis
4. Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation
5. Design, synthesis, and evaluation of thiazolecarboxamide derivatives as stimulator of interferon gene inhibitors
6. Synthesis and evaluation of hybrid molecules as RIPK1 and HDACs dual inhibitors
7. 13,14-seco withaphysalins from Physalis minima and their inhibitory effects on NLRP3 inflammasome activation
8. Identification of benzo[b]thiophene-1,1-dioxide derivatives as novel PHGDH covalent inhibitors
9. Integrated multi-omics analysis reveals gut microbiota dysbiosis and systemic disturbance in major depressive disorder
10. Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors
11. Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
12. SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
13. Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors
14. Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma
15. Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis
16. Structure−Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists
17. Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase
18. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration
19. Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold
20. Discovery and optimization of 3‐(indolin‐5‐yloxy)pyridin‐2‐amine derivatives as potent necroptosis inhibitors.
21. Pharmacokinetics, distribution, and excretion of sodium oligomannate, a recently approved anti-Alzheimer's disease drug in China
22. Structural insights into a shared mechanism of human STING activation by a potent agonist and an autoimmune disease-associated mutation
23. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma
24. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation
25. Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors
26. Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors
27. GV‐971 attenuates the progression of neuromyelitis optica in murine models and reverses alterations in gut microbiota and associated peripheral abnormalities.
28. Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer
29. A novel strategy for treating oncogene‐mutated tumors by targeting tumor microenvironment and synergistically enhancing anti‐PD‐1 immunotherapy
30. Discovery of hematopoietic progenitor kinase 1 inhibitors using machine learning-based screening and free energy perturbation
31. Low‐Dose Chemotherapy Preferentially Shapes the Ileal Microbiome and Augments the Response to Immune Checkpoint Blockade by Activating AIM2 Inflammasome in Ileal Epithelial Cells
32. 13,14-Seco Withaphysalins from Physalis Minima and Their Inhibitory Effects on Nlrp3 Inflammasome Activation
33. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
34. Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
35. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors
36. Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure–activity relationship, crystal structural characterization and in vivo study
37. Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction
38. Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma
39. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
40. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis
41. Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
42. Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors
43. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs
44. Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy
45. Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation
46. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression
47. A novel STING agonist with systemic and durable anti‐tumour activity
48. Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition
49. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors
50. Design, synthesis and pharmacological evaluation of 4,5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.